Accustem Sciences (ACUT) Common Equity (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Common Equity of -$3.9 million for Q1 2026, down 79.56% year-over-year from -$18.9 million in Q1 2025, and down 13.84% quarter-over-quarter from -$3.4 million in Q4 2025.
Accustem Sciences (ACUT) Common Equity (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Common Equity for 6 consecutive years, with -$3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 79.56% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$3.9 million (down 79.56% YoY), while the FY2025 annual figure was -$3.4 million, down 2.67% from the prior year.
- Common Equity slipped to -$3.9 million in Q1 2026 per ACUT's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Common Equity topped out at $2.7 million in Q1 2022 and bottomed at -$3.9 million in Q1 2026.
- Historically, Common Equity has averaged -$1.7 million across 5 years, with a median of -$2.2 million in 2025.
- Annual changes were most pronounced in 2022 — Common Equity surged 105.37% — and 2023, when it slumped 1413.14%.
- Accustem Sciences' Common Equity stood at -$139550.0 in 2022, then plunged by 1413.14% to -$2.1 million in 2023, then slumped by 56.91% to -$3.3 million in 2024, then dropped by 2.67% to -$3.4 million in 2025, then fell by 13.84% to -$3.9 million in 2026.
- Business Quant data shows ACUT's Common Equity at -$3.9 million in Q1 2026, -$3.4 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.79 Bn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | -4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87 Mn |
| Dec 31, 2025 | -3.40 Mn |
| Sep 30, 2025 | -2.91 Mn |
| Jun 30, 2025 | -2.53 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | -3.31 Mn |
| Sep 30, 2024 | -3.19 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Mar 31, 2024 | -2.62 Mn |
| Dec 31, 2023 | -2.11 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -946,682.00 |
| Dec 31, 2022 | -139,550.00 |
| Sep 30, 2022 | 797,724.00 |
| Jun 30, 2022 | 1.65 Mn |
| Mar 31, 2022 | 2.69 Mn |
| Dec 31, 2021 | 650,673.00 |
| Sep 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 1.26 Mn |